Biocad
Biosimilar developer, Russia. 3 development products across 3 molecules: infliximab, rituximab, trastuzumab.
About Biocad
Biocad, Russia's largest biotechnology company, is the only foreign biosimilar developer with a broad Indian presence outside the seven regulators' home markets. It holds Indian import permissions for its rituximab, trastuzumab and infliximab, granted between 2017 and 2019.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Infliximab | Biocad infliximab BCD-055 | · | · | · | · | · | Dec 2019 | · | 1/7 |
| Rituximab | Biocad rituximab BCD-020 | · | · | · | · | · | Jul 2017 | · | 1/7 |
| Trastuzumab | Biocad trastuzumab BCD-022 | · | · | · | · | · | Apr 2018 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
In development
ClinicalTrials.gov lists ten comparative trials sponsored by Biocad for seven molecules: adalimumab, bevacizumab, filgrastim, infliximab, pertuzumab, rituximab, trastuzumab. Candidates without an approval yet in the seven markets: BCD-021, BCD-057, BCD-178, Leucostim.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | BCD-057 | Biocad | Humira | Phase 3 | Comparative efficacy | Completed | Dec 2016 | Dec 2017 | no approval in the seven markets | NCT02762955 |
| Adalimumab | BCD-057 | Biocad | Humira | Phase 1 | Comparative PK | Completed | Jun 2015 | Oct 2015 | no approval in the seven markets | NCT02395055 |
| Bevacizumab | BCD-021 | Biocad | Avastin | Phase 3 | Comparative efficacy | Completed | Oct 2012 | Nov 2014 | no approval in the seven markets | NCT01763645 |
| Filgrastim | Leucostim | Biocad | Neupogen | Phase 1 | Comparative PK | Completed | Jul 2016 | Nov 2016 | no approval in the seven markets | NCT02762799 |
| Infliximab | BCD-055 | Biocad | Remicade | Phase 3 | Comparative efficacy | Completed | Jan 2016 | May 2017 | Biocad infliximab | NCT02762812 |
| Infliximab | BCD-055 | Biocad | Remicade | Phase 3 | Comparative efficacy | Completed | Jan 2016 | Jul 2018 | Biocad infliximab | NCT02762838 |
| Pertuzumab | BCD-178 | Biocad | Perjeta | Phase 1 | Comparative PK | Unknown, last active, not recruiting | Aug 2022 | Apr 2023 | no approval in the seven markets | NCT05738993 |
| Rituximab | BCD-020 | Biocad | MabThera | Phase 3 | Comparative efficacy | Completed | Dec 2012 | Jul 2015 | Biocad rituximab | NCT01759030 |
| Rituximab | BCD-020 | Biocad | MabThera | Phase 3 | Comparative efficacy | Completed | Sep 2011 | Jan 2017 | Biocad rituximab | NCT01701232 |
| Trastuzumab | BCD-022 | Biocad | Herceptin | Phase 3 | Comparative efficacy | Completed | Oct 2012 | Mar 2015 | Biocad trastuzumab | NCT01764022 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with Biocad, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOJul 2017Biocad India (INN only), rituximab
- CDSCOApr 2018Biocad India (INN only), trastuzumab
- CDSCODec 2019Biocad India (INN only), infliximab
Compare Biocad with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant